Rheumatoid ArthritisPhase 3NCT00951275
A Study of Tocilizumab + DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis
A Phase 3 study testing tocilizumab [RoActemra/Actemra] and Standard DMARDs (Disease Modifying Anti Rheumatic Drugs) in people with Rheumatoid Arthritis, run by Hoffmann-La Roche at 27 sites in Italy.
Trial summary
This single arm study will assess the effect of tocilizumab + DMARDs (Disease Modifying Anti-Rheumatic Drugs)on improvement of anemia and fatigue in patients with moderate to severe active rheumatoid arthritis. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Rheumatoid Arthritis
- What is being tested?
- tocilizumab [RoActemra/Actemra] and Standard DMARDs (Disease Modifying Anti Rheumatic Drugs)
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 105 participants
- Where
- 27 sitesItaly
- Study dates
- 31 Oct 2009to 22 Jul 2011
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- adult patients, >=18 years of age;
- rheumatoid arthritis >=6 months duration;
- DAS28>=3.2;
- inadequate response to prior treatment with a stable dose (>=8 weeks) of DMARD therapy.
Who cannot join
- rheumatic autoimmune disease other than rheumatoid arthritis;
- history of or current inflammatory joint disease other than rheumatoid arthritis;
- unsuccessful treatment with an anti-TNF agent;
- previous/concurrent treatment with any cell-depleting therapies.
Trial locations and contacts
27 sites in 1 country.
27 sites in 1 country
Italy27 sites
Azienda Ospedaliera Rummo; Divisione Di Reumatologia
Benevento, Campania, 82100
ASST PAPA GIOVANNI XXIII; Reumatologia Day Hospital-Torre 2 terzo piano
Bergamo, Lombardy, 24127
A.O.U Policlinico S. Orsola Malpighi di Bologna U.O di Medicina Interna Borghi - Pad.2
Bologna, Emilia-Romagna, 40138
Ospedale Perrino; Medicina Interna - Divisione di Reumatologia
Brindisi, Apulia, 72100
Ospedale Vittorio Emanuele Ii; U.O. Reumatologia Clinica Medica Condorelli
Catania, Sicily, 95124
A.U.O. G. Martino- Policlinico Univ. Gazzi; Dept. Di Medicina Interna, Divisione Di Reumatologia
Gazzi, Sicily, 98125
Presidio Ospedaliero Valle D'itria; Divisione Di Nefrologia
Martina Franca, Apulia, 74015
Ospedale Di Massa; Divisione Di Reumatologia
Massa, Tuscany, 54100
ASST DI MONZA; Reumatologia (Medicina I)
Monza, Lombardy, 20052
Azienda Ospedaliera A. Cardarelli; Medicina III - Divisione di Reumatologia
Naples, Campania, 80131
UNIVERSITÀ DI NAPOLI FEDERICO II; Dipartimento di Immunologia Clinica ed Allergologia
Naples, Campania, 80131
Arnas Ospedale Civico; Medicina Interna II
Palermo, Sicily, 90127
Az. Osp. Villa Sofia; Unità Operativa Reumatologia
Palermo, Sicily, 90146
Ospedali Riuniti Villa Sofia- Cervello X; Divisione Medicina I
Palermo, Sicily, 90146
Az. Ospedaliera Univ. di Parma; Medicina Interna e Reumatologia
Parma, Emilia-Romagna, 43100
Ospedale Guglielmo Da Saliceto Unità Operativa Semplice di Reumatologia e Immunologia
Piacenza, Emilia-Romagna, 29100
Policlinico Tor Vergata; Divisione Di Reumatologia
Rome, Lazio, 00133
Ospedale Nuovo Regina Margherita; Divisione di Medicina Interna Reumatologia
Rome, Lazio, 00153
Ospedale S.Pietro Fatebenefratelli; Divisione di Reumatologia
Rome, Lazio, 00189
IRCCS Istituto Clinico Humanitas; Immunologia Clinica E Reumatologia
Rozzano, Lombardy, 20089
Ospedale Galateo; U.O. Di Reumatologia
San Cesario di Lecce, Apulia, 73016
Ospedale San Paolo; Divisione di Reumatologia
Savona, Liguria, 17100
Ospedale M. Scarlato - Asl Sa1; U.O. Di Reumatologia
Scafati, Campania, 84018
Irccs Fondazione Salvatore Maugeri-Istituto Scientifico Di Telese;U.O. Riabilitazione Reumatologica
Telese Terme, Campania, 82037
Ospedale S. Giovanni Bosco; S.C. A Direzione Uni Ria Di Immunologia Clinica
Turin, Piedmont, 10154
Ospedale SS Giovanni e Paolo; Divisione Di Reumatologia
Venezia, Veneto, 30127
Ospedale Belcolle; Divisione Di Reumatologia
Viterbo, Lazio, 01100
About this study
Official title: A Single Arm, Open-label Study of Early Improvement of Anemia and Fatigue During Treatment With Tocilizumab (TCZ) in Combination With DMARDs, in Adult Patients With Moderate to Severe Active Rheumatoid Arthritis.
This single arm study will assess the effect of tocilizumab + DMARDs (Disease Modifying Anti-Rheumatic Drugs)on improvement of anemia and fatigue in patients with moderate to severe active rheumatoid arthritis. Eligible patients who have had an inadequate response to DMARDs will receive tocilizumab 8mg/kg iv every 4 weeks in combination with standard DMARDs, for 6 months. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.
- Conditions
- Rheumatoid Arthritis
- Being tested
- tocilizumab [RoActemra/Actemra], Standard DMARDs (Disease Modifying Anti Rheumatic Drugs)
- Medical subject headings
- Arthritis, Rheumatoid
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
tocilizumab [RoActemra/Actemra]Drug
8mg/kg iv every 4 weeks for 6 months
Standard DMARDs (Disease Modifying Anti Rheumatic Drugs)Drug
As prescribed
| Study group | Role | What they receive |
|---|---|---|
| 1 | Experimental | Not described Receives: Drug: tocilizumab [RoActemra/Actemra]; Drug: Standard DMARDs (Disease Modifying Anti Rheumatic Drugs) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Improvement of Anemia at Week 4 Assessed as Change From Baseline in Hemoglobin
Hemoglobin levels were measured as grams/deciliter (g/dL).
Measured: Week 4
Improvement in Fatigue at Week 4 Assessed as Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scores
The FACIT-Fatigue score was calculated according to a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participants fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). Clinically relevant improvement is defined as a greater than or equal to (≥)5-point change from Baseline.
Measured: Week 4
Secondary outcomes (25)
Mean Hemoglobin Levels During the Study
Measured: Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24
Improvement of Anemia Assessed as Change From Baseline in Hemoglobin
Improvement of anemia was evaluated as change in hemoglobin levels from baseline.
Measured: Weeks 2, 4, 8, 12, 16, 20, and 24
FACIT-F Scores
The FACIT-Fatigue score was calculated according to a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participants fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). Clinically relevant improvement is defined as a ≥5-point change from Baseline.
Measured: Baseline, Weeks 2, 4, 8,12, 16, 20 and 24
Improvement of Fatigue Assessed as Change From Baseline in FACIT-F Scores
The FACIT-Fatigue score was calculated according to a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participants fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). Clinically relevant improvement is defined as a ≥5-point change from Baseline.
Measured: Weeks 2, 4, 8, 12, 16, 20 and 24
Percentage of Participants Achieving American College of Rheumatology (ACR) 20 Percent (%), 50% or 70% Improvement
The ACR response rates ACR20, ACR50, and ACR70 were defined as ≥20%, ≥50% and ≥ 70% improvement, respectively, in: swollen joint count (SJC) (66 joints) and tender joint count (TJC) (68 joints) and 3 of the 5 remaining ACR parameters: Patient assessment of pain; Patient Global Assessment of Disease Activity; Investigator Global Assessment of Disease Activity; participant self-rated assessment of disability measured by the Health Assessment Questionnaire Disability Index (HAQ-DI); and acute phase response (erythrocyte sedimentation rate [ESR] or C-reactive protein [CRP]).
Measured: Week 24
Percent Change From Baseline to Week 24 in TJC
Sixty-eight (68) joints were assessed at each visit for tenderness; joints were assessed and classified as tender/not tender. Tender joint count 68 (TJC-68) was calculated as the number of tender joints from 68 joints; the number of tender joints was summed (maximum score 68). Calculated values were used for the analysis. A negative score indicated improvement.
Measured: Week 24
Percent Change From Baseline to Week 24 in SJC
Sixty-six (66) joints were assessed at each visit for swelling; joints were assessed and classified as swollen/not swollen. Swollen joint count 66 (SJC-66) was calculated as the number of swollen joints from 66 joints; the number of swollen joints was summed (maximum score 66). Calculated values were used for the analysis. A negative score indicated improvement.
Measured: Week 24
Percent Change From Baseline to Week 24 in Patient Global Assessment of Pain
The participant's assessment of their current level of pain was displayed on a 100-millimeter (mm) horizontal visual analog scale (VAS). The left-hand extreme of the line was described as "no pain" and the right-hand as "unbearable pain". The participant was asked to mark the line that corresponded to their current level of pain; the distance from the left edge was recorded.
Measured: Week 24
Percent Change From Baseline to Week 24 in Patient's Global Assessment of Disease Activity
The participant's overall assessment of their current disease activity was displayed on a 100-mm horizontal VAS. The left-hand extreme of the line was described as "no disease activity" (symptom free and no arthritis symptoms) and the right-hand extreme as "maximum disease activity" (maximum arthritis disease activity). Participants were asked to assess their current level of disease activity and mark the line; the distance from the left edge was recorded.
Measured: Week 24
Percent Change From Baseline to Week 24 in Investigator's Global Assessment of Disease Activity
The physician's assessment of the participant's current disease activity was displayed on a 100-mm horizontal VAS. The left-hand extreme of the line was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme was considered "maximum disease activity". The physician's global assessment of disease activity was completed by the Efficacy Assessor who could or could not be a physician. The assessor was asked to mark the line corresponding to their assessment of the participant's present level of disease activity; the distance from the left edge was recorded.
Measured: Week 24
Percent Change From Baseline to Week 24 in HAQ-DI
HAQ-DI includes 20 questions concerning participant's activities of daily life, grouped in 8 scales of 2 to 3 questions for each activity. To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen. Overall score was computed as the sum of the domain scores and divided by the number of domains answered. Total possible score range was 0-3 where 0 (equals)=without difficulties; 1= with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all.
Measured: Week 24
Percent Change From Baseline to Week 24 in High-Sensitivity CRP (Hs-CRP)
hs-CRP is an acute phase reactant protein that is a clinical marker for Rheumatoid Arthritis (RA). hsCRP is measured in milligrams per liter (mg/L).
Measured: Week 24
Percent Change From Baseline to Week 24 in ESR
ESR is a blood test used to monitor therapy in inflammatory diseases such as RA and reflects acute phase reactant levels. ESR is measured in mm per hour (mm/hr); active disease in RA is defined by an ESR greater than 30 mm/hr.
Measured: Week 24
Percentage of Participants With a Response at Week 24 by European League Against Rheumatism (EULAR) Category
Disease response was assessed using EULAR Disease Activity Score Based on 28-Joint Count (DAS28) categories of Good, Moderate, or No Response. Good response was defined as a DAS28 score of less than (<)3.2 and improvement from baseline of >1.2; Moderate response was defined as a DAS28 score of 3.2-5.1 and improvement from baseline of 1.2-0.6 or a DAS28 score of >5.1 and improvement from baseline of >1.2; No response was defined as a DAS28 score of >5.1 and improvement from baseline of <1.2. Participants who discontinued prematurely were identified as non-responders.
Measured: Week 24
Percentage of Participants With a Response at Week 24 by DAS28 Category
DAS28 calculated from the number of swollen joints (SJC) and tender joints (TJC) using the 28 joints count, the ESR (mm/hr) and patient's global assessment of disease activity (participant rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 ≤3.2=low disease activity, DAS28 >5.1=high disease activity and DAS <2.6=remission.
Measured: Week 24
Percent Change From Baseline to Week 24 in DAS28 Score
DAS28 calculated from the number of swollen joints (SJC) and tender joints (TJC) using the 28 joints count, the ESR (mm/hr) and patient's global assessment of disease activity (participant rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 ≤3.2=low disease activity, DAS28 >5.1=high disease activity and DAS <2.6=remission.
Measured: Week 24
Percentage of Participants With an Improvement of ≥1 g/dL in Hemoglobin
Measured: Week 24
Number of Days as Assessed by Short Form-Health and Labour Questionnaire (SF-HLQ)
The SF-HLQ assessed productivity losses related to health problems in individuals with paid or unpaid work and consists of three modules (absenteeism from paid work, production losses without absenteeism from paid work and hindrance in the performance of paid and unpaid work). Any missed working days or number of worked days with reduced efficiency during the last month were reported.
Measured: Baseline
Change From Baseline to Weeks 12 and 24 in Number of Days as Assessed by SF-HLQ
The SF-HLQ assessed productivity losses related to health problems in individuals with paid or unpaid work and consists of three modules (absenteeism from paid work, production losses without absenteeism from paid work and hindrance in the performance of paid and unpaid work). Any missed working days or number of worked days with reduced efficiency during the last month were reported.
Measured: Weeks 12 and 24
Number of Hours as Assessed by SF-HLQ
Number of working hours lost, and number of hours of support in in taking over and performing usual household tasks in the last month: chores done by family members, chores done by other persons receiving no pay, home care, other paid care, total number of unpaid hours, and total number of hours during the last month were reported.
Measured: Baseline
Change From Baseline to Weeks 12 and 24 in Number of Hours as Assessed by SF-HLQ
Number of working hours lost, and number of hours of support in in taking over and performing usual household tasks in the last month: chores done by family members, chores done by other persons receiving no pay, home care, other paid care, total number of unpaid hours, and total number of hours during the last month were reported. Changes from baseline were only calculated in participants who completed the questionnaire at all times (baseline, Week 12, and Week 24). Negative number indicates improvement.
Measured: Baseline
SF-HLQ Hindrance Score
Participants were asked if their health problems hindered their paid work on a scale of 1 to 3 (1=no, 2=yes, slightly, 3=yes, very much) and their unpaid work including household work, going shopping, odd jobs, specific activities sharing the household on a scale of 0 to 3 (0=performed without being bothered by healthy problems; 1=performed although bothered by health problems; 2=not performed because of health problems; 3=not performed for reasons other than health problems). The total hindrance score for unpaid work was derived by adding up the item scores. This hindrance score is a measure of the hindrance experienced as a result of health problems during the performance of unpaid work. The minimum score per item for hindrance score was 0, maximum score was 2 (Score of 3 was not considered since the reasons were "other than health problems"). Total score was calculated by adding all 4 items together and ranged from 0 (best possible score) to 8 (worst possible score).
Measured: Baseline
Change From Baseline to Weeks 12 and 24 SF-HLQ Hindrance Score
Participants were asked if health problems hindered their paid work on a scale of 1 to 3 (1=no, 2=yes, slightly, 3=yes, very much) and their unpaid work including household work, going shopping, odd jobs, specific activities sharing the household on a scale of 0 to 3 (0=performed without being bothered by healthy problems; 1=performed although bothered by health problems; 2=not performed because of health problems; 3=not performed for reasons other than health problems). Hindrance score is a measure of the hindrance experienced as a result of health problems during the performance of unpaid work. The minimum score per item for hindrance score was 0, maximum score was 2 (Score of 3 was not considered since the reasons were "other than health problems"). Total score was calculated by adding all 4 items together and ranged from 0 (best possible score) to 8 (worst possible score). A negative change from baseline indicates improvement.
Measured: Baseline
Efficiency as Assessed by SF-HLQ
Participants were ask to rate their efficiency in working on a scale of of 0 to 10 (0=very worse, 10=as usual). Overall efficiency score was based on the first 6 items of Question 6, which is a descriptive instrument comprised of 7 items designed to evaluate the specific problems affecting production. These 7 items relate to the effect of health problems on concentration, work pace, the need to be alone, making decisions, postponing and transferring work to others. The participant can choose from 4 possible answers: (almost) never, sometimes, often and (nearly) always. Efficiency score range=6 to 24; higher scores indicate higher impairment.
Measured: Baseline
Change From Baseline to Weeks 12 and 24 in Efficiency as Assessed by SF-HLQ
Participants were ask to rate their efficiency in working on a scale of of 0 to 10 (0=very worse, 10=as usual). Overall efficiency score was based on the first 6 items of Question 6, which is a descriptive instrument comprised of 7 items designed to evaluate the specific problems affecting production. These 7 items relate to the effect of health problems on concentration, work pace, the need to be alone, making decisions, postponing and transferring work to others. The participant can choose from 4 possible answers: (almost) never, sometimes, often and (nearly) always. Efficiency score range=6 to 24; higher scores indicate higher impairment. Change from baseline was only calculated for participants who completed the questionnaire at all times (baseline, Week 12 and Week 24). A negative change from baseline indicates improvement.
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Aug 2009 (estimated)
- Study start31 Oct 2009
- Primary completion22 Jul 2011
- Study completion22 Jul 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Rheumatoid ArthritisStudies of the same condition, open and under way.
- More trials run by Hoffmann-La RocheThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 105 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hoffmann-La Roche
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Trials, Study director, Hoffmann-La Roche
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00951275
- Sponsor's protocol ID
- ML22462
- Other IDs
- 2009-011105-17, 2009
- Status last verified
- Jun 2017
- First submitted
- 30 Jul 2009
- Last updated
- 3 Aug 2017
- Results posted
- Yes, on ClinicalTrials.gov
Study at a glance
From the registry record, last updated by the sponsor on 3 Aug 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Single Arm, Open-label Study of Early Improvement of Anemia and Fatigue During Treatment With Tocilizumab (TCZ) in Combination With DMARDs, in Adult Patients With Moderate to Severe Active Rheumatoid Arthritis.
- ClinicalTrials.gov ID
- NCT00951275
- Acronym / sponsor ID
- ML22462
- Conditions
- Rheumatoid Arthritis
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 105 participants (actual)
- Lead sponsor
- Hoffmann-La RocheIndustry (pharma, biotech, devices)
- Study start
- 31 Oct 2009 (actual)
- Primary completion
- 22 Jul 2011 (actual)
- Study completion
- 22 Jul 2011 (actual)
- First posted
- 4 Aug 2009 (estimated)
- Results
- Posted 12 Aug 2014
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This single arm study will assess the effect of tocilizumab + DMARDs (Disease Modifying Anti-Rheumatic Drugs)on improvement of anemia and fatigue in patients with moderate to severe active rheumatoid arthritis. Eligible patients who have had an inadequate response to DMARDs will receive tocilizumab 8mg/kg iv every 4 weeks in combination with standard DMARDs, for 6 months. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| 1 | Experimental | Drug: tocilizumab [RoActemra/Actemra], Drug: Standard DMARDs (Disease Modifying Anti Rheumatic Drugs) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- adult patients, >=18 years of age;
- rheumatoid arthritis >=6 months duration;
- DAS28>=3.2;
- inadequate response to prior treatment with a stable dose (>=8 weeks) of DMARD therapy.
Key exclusion criteria (4 listed)
- rheumatic autoimmune disease other than rheumatoid arthritis;
- history of or current inflammatory joint disease other than rheumatoid arthritis;
- unsuccessful treatment with an anti-TNF agent;
- previous/concurrent treatment with any cell-depleting therapies.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| tocilizumab [RoActemra/Actemra]8mg/kg iv every 4 weeks for 6 months | Drug | 1 |
| Standard DMARDs (Disease Modifying Anti Rheumatic Drugs)As prescribed | Drug | 1 |
Primary outcome
Improvement of Anemia at Week 4 Assessed as Change From Baseline in Hemoglobin
Time frame: Week 4
Hemoglobin levels were measured as grams/deciliter (g/dL).
Improvement in Fatigue at Week 4 Assessed as Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scores
Time frame: Week 4
The FACIT-Fatigue score was calculated according to a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participants fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). Clinically relevant improvement is defined as a greater than or equal to (≥)5-point change from Baseline.
25 secondary outcomes
Mean Hemoglobin Levels During the Study
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24
Improvement of Anemia Assessed as Change From Baseline in Hemoglobin
Time frame: Weeks 2, 4, 8, 12, 16, 20, and 24
FACIT-F Scores
Time frame: Baseline, Weeks 2, 4, 8,12, 16, 20 and 24
Improvement of Fatigue Assessed as Change From Baseline in FACIT-F Scores
Time frame: Weeks 2, 4, 8, 12, 16, 20 and 24
Percentage of Participants Achieving American College of Rheumatology (ACR) 20 Percent (%), 50% or 70% Improvement
Time frame: Week 24
Percent Change From Baseline to Week 24 in TJC
Time frame: Week 24
Percent Change From Baseline to Week 24 in SJC
Time frame: Week 24
Percent Change From Baseline to Week 24 in Patient Global Assessment of Pain
Time frame: Week 24
Percent Change From Baseline to Week 24 in Patient's Global Assessment of Disease Activity
Time frame: Week 24
Percent Change From Baseline to Week 24 in Investigator's Global Assessment of Disease Activity
Time frame: Week 24
Percent Change From Baseline to Week 24 in HAQ-DI
Time frame: Week 24
Percent Change From Baseline to Week 24 in High-Sensitivity CRP (Hs-CRP)
Time frame: Week 24
Percent Change From Baseline to Week 24 in ESR
Time frame: Week 24
Percentage of Participants With a Response at Week 24 by European League Against Rheumatism (EULAR) Category
Time frame: Week 24
Percentage of Participants With a Response at Week 24 by DAS28 Category
Time frame: Week 24
Percent Change From Baseline to Week 24 in DAS28 Score
Time frame: Week 24
Percentage of Participants With an Improvement of ≥1 g/dL in Hemoglobin
Time frame: Week 24
Number of Days as Assessed by Short Form-Health and Labour Questionnaire (SF-HLQ)
Time frame: Baseline
Change From Baseline to Weeks 12 and 24 in Number of Days as Assessed by SF-HLQ
Time frame: Weeks 12 and 24
Number of Hours as Assessed by SF-HLQ
Time frame: Baseline
Change From Baseline to Weeks 12 and 24 in Number of Hours as Assessed by SF-HLQ
Time frame: Baseline
SF-HLQ Hindrance Score
Time frame: Baseline
Change From Baseline to Weeks 12 and 24 SF-HLQ Hindrance Score
Time frame: Baseline
Efficiency as Assessed by SF-HLQ
Time frame: Baseline
Change From Baseline to Weeks 12 and 24 in Efficiency as Assessed by SF-HLQ
Time frame: Baseline
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Aug 2017.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Rheumatoid Arthritis
RecruitingPhase 2
Study of PTC844 in Participants With Active Rheumatoid Arthritis
Rheumatoid Arthritis
Not yet recruitingPhase 1
An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)
Rheumatoid Arthritis and Systemic Lupus Erythematosus
Not yet recruitingPhase 1
R-2487 in Patients With Sjogren's Syndrome (SjD)
Sjogren's Syndrome, Sjögren
RecruitingPhase 1
A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body
Rheumatoid Arthritis, Systemic Lupus Erythematosus
Active, not recruitingPhase 2
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Trials study director
Hoffmann-La Roche
27 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing tocilizumab [RoActemra/Actemra] and Standard DMARDs (Disease Modifying Anti Rheumatic Drugs) in people with Rheumatoid Arthritis, run by Hoffmann-La Roche at 27 sites in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Aug 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 27 sites in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 12 Aug 2014). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Improvement of Anemia at Week 4 Assessed as Change From Baseline in Hemoglobin (time frame: Week 4). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Aug 2017.